All In Biotech

Drug Trial Radar · NCT03984591

A Registry-based Cluster Randomized Trial to Compare the Effect of Spironolactone vs. Eplerenone on Clinical Outcomes in Patients With Symptomatic Systolic Heart Failure

Cluster and Registry Trials Of the Working Group of Heart Failure in Denmark: Are SPironolactone and Eplerenone Comparable Treatments?

Last checked: Nov 20, 2026Latest source record: Feb 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingRandomized with 7,200 participants. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

7,200

Planned (sponsor's estimate)

Start

Nov 1, 2020

Primary completion

Dec 31, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Bispebjerg HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Copenhagen University Hospital, Rigshospitalet
First posted
Jun 13, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Objective The objective is to compare the efficacy of spironolactone and eplerenone on clinical outcome in patients with heart failure and a reduced ejection fraction. Method The study is a crossover cluster randomized trial. Each heart failure clinic in Denmark will be allocated to four periods (clusters): two periods with spironolactone and two periods with eplerenone as first drug. The planned total participation time for each department is 4 years and we estimate that data from 7200 patients will be accrued in this period. Endpoints will be assessed through Danish National Registries.

Conditions

  • Systolic Heart Failure

Interventions

  • EplerenoneDrug

    Eplerenone according to guidelines

  • SpironolactoneDrug

    Spironolactone according to guidelines

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MortalityTime frame: 5 years
  2. Mortality or hospitalization for heart failureTime frame: 6 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bispebjerg Hospital

    Copenhagen, Denmark

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.